NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Shanghai Ark Biopharmaceutical Co., Ltd.

Shanghai Ark Biopharmaceutical Co., Ltd.

Private
ShanghaiHealthcare & Life Scienceshttps://arkbiosciences.com/

Last Round

Series D

Jul 14, 2022

Est. Valuation

$694.8M

Total Funding Raised

$146.3M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Shanghai Ark Biopharmaceutical Co., Ltd. is a biopharmaceutical company that discovers and develops therapeutics for unmet medical needs in respiratory and pediatric diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B2C

Customer Profile

Hardware Sales, Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

respiratory therapeuticsRSV treatmentbiotechnologyRSVADHD treatmentADHDpediatric therapeuticsdrug discoverysmall molecule drugsclinical developmentinfectious disease therapeuticsIPF treatmentIPFdrug in-licensingmonoclonal antibodymAbsRSV fusion inhibitor

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Shanghai Ark Biopharmaceutical Co., Ltd. Comparables

Compare Shanghai Ark Biopharmaceutical Co., Ltd. with similar companies based on industry and business-model similarity.

Shanghai Ark Biopharmaceutical Co., Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Enanta Pharmaceuticals
77%
Pfizer
77%
Sanofi
71%

Shanghai Ark Biopharmaceutical Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DJul 14, 2022
Series CJan 22, 2021
Series A ExtensionFeb 6, 2017
Series AApr 9, 2015
AngelFeb 1, 2014

Shanghai Ark Biopharmaceutical Co., Ltd. Investors

Notable investors and investment history

Shanghai Ark Biopharmaceutical Co., Ltd. investors
InvestorRounds
Oriental Fortune CapitalSeries C
Loyal Valley CapitalSeries D
Oriza HoldingsSeries C, Series D
Hillhouse InvestmentSeries C
Daoyuan CapitalSeries C
德同资本Series C
Jiangsu Ruihua Investment Holding GroupSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 15, 2026

    Monthly visitors increased 268% MoM.

  • Jan 20, 2026

    Monthly visitors increased 189% MoM, reaching 503.

Shanghai Ark Biopharmaceutical Co., Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Shanghai Ark Biopharmaceutical Co., Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Shanghai Ark Biopharmaceutical Co., Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Employee Range14
Year Founded2014
Last FundingJul 14, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.